NEW YORK (Reuters) – The head of the U.S. Food & Drug Administration Scott Gottlieb said on Wednesday that he was concerned about the impact of deals like the CVS Health purchase of Aetna Inc on the ability of pharmaceutical companies to block the entry of cheaper copycat drugs.